Research graph
References from Circulating phosphatidylserine as a plasma biomarker for clinical staging and prognostic prediction in Parkinson's disease: A diagnostic validation study. Local targets link to admitted publications; unresolved targets remain external evidence.
Pain in Parkinson's disease: pathophysiology, classification and treatment
10.31083/j.jin2205132 · 2023 · External reference
Parkinson's disease
10.1056/nejmra2401857 · 2024 · External reference
Challenges in the diagnosis of Parkinson's disease
10.1016/s1474-4422(21)00030-2 · 2021 · External reference
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
10.1016/s1474-4422(23)00405-2 · 2024 · External reference
Spontaneous apoptosis of cells in therapeutic stem cell preparation exert immunomodulatory effects through release of phosphatidylserine
10.1038/s41392-021-00688-z · 2021 · External reference
Hyperinflammation, apoptosis, and organ damage
10.1177/15353702221090454 · 2022 · External reference
Redistribution of the glycocalyx exposes phagocytic determinants on apoptotic cells
10.1016/j.devcel.2024.01.020 · 2024 · External reference
Nanoscale imaging of CD47 informs how plasma membrane modifications shape apoptotic cell recognition
10.1038/s42003-023-04558-y · 2023 · External reference
Phosphatidylserine enrichment in the nuclear membrane regulates key enzymes of phosphatidylcholine synthesis
10.1038/s44318-024-00151-z · 2024 · External reference
Lipid- and phospho-regulation of CTP:phosphocholine cytidylyltransferase α association with nuclear lipid droplets
10.1091/mbc.e23-09-0354 · 2024 · External reference
Apoptotic extracellular vesicle formation via local phosphatidylserine exposure drives efficient cell extrusion
10.1016/j.devcel.2023.05.008 · 2023 · External reference
An apoptotic 'eat me' signal: phosphatidylserine exposure
10.1016/j.tcb.2015.08.003 · 2015 · External reference
Apoptotic vesicles ameliorate lupus and arthritis via phosphatidylserine-mediated modulation of T cell receptor signaling
2023 · External reference
Copper chelate targeting externalized phosphatidylserine inhibits PD-L1 expression and enhances Cancer immunotherapy
10.1021/jacs.4c14394 · 2025 · External reference
Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson's disease
10.1016/j.xcrm.2022.100661 · 2022 · External reference
[new diagnostic criteria for Parkinson's disease: MDS-PD criteria]. Brain and nerve =
2018 · External reference
Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times
10.1002/mds.22875 · 2010 · External reference
Montreal cognitive assessment scale in patients with Parkinson disease with normal scores in the Mini-mental state examination
10.1590/1980-57642018dn13-010008 · 2019 · External reference
People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance
10.1002/mds.25924 · 2014 · External reference
Brief psychiatric screening questionnaire in Parkinson's disease
2019 · External reference
Guidelines for Parkinson's disease treatment: consensus from the movement disorders scientific Department of the Brazilian Academy of neurology - motor symptoms
10.1590/0004-282x-anp-2021-0219 · 2022 · External reference
Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS part III
10.1177/1877718x241302337 · 2025 · External reference
Barthel index and modified Rankin scale: psychometric properties during medication phases in idiopathic Parkinson disease
10.1016/j.rehab.2019.08.006 · 2020 · External reference
Parkinson's disease and MicroRNAs: a duel between inhibition and stimulation of apoptosis in neuronal cells
10.1007/s12035-024-04111-w · 2024 · External reference
An insight into the molecular mechanism of mitochondrial toxicant-induced neuronal apoptosis in Parkinson's disease
10.2174/1566524022666220203163631 · 2023 · External reference
Astragaloside IV- and nesfatin-1-encapsulated phosphatidylserine liposomes conjugated with wheat germ agglutinin and leptin to activate anti-apoptotic pathway and block phosphorylated tau protein expression for Parkinson's disease treatment
10.1016/j.msec.2021.112361 · 2021 · External reference
Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder
10.1212/wnl.0000000000003680 · 2017 · External reference
Brain metabolic abnormalities during gait with freezing in Parkinson's disease
10.1016/j.neuroscience.2015.08.063 · 2015 · External reference
A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity
10.1186/s12987-020-00230-3 · 2020 · External reference
Alpha-synuclein as a biomarker of Parkinson's disease: good, but not good enough
10.3389/fnagi.2021.702639 · 2021 · External reference
Validation of serum neurofilament light chain as a biomarker of Parkinson's disease progression
10.1002/mds.28206 · 2020 · External reference
Associations of sleep disorders with serum neurofilament light chain levels in Parkinson's disease
10.1186/s12883-024-03642-y · 2024 · External reference
Cognitive reserve in ageing and Alzheimer's disease
10.1016/s1474-4422(12)70191-6 · 2012 · External reference
Sex and gender differences in cognitive resilience to aging and Alzheimer's disease
10.1002/alz.13844 · 2024 · External reference
Mitochondrial dysfunction and oxidative stress in Alzheimer's disease, and Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis -an updated review
10.1016/j.mito.2023.05.007 · 2023 · External reference
Mitochondrial dysfunction in Parkinson's disease
10.1111/jnc.13731 · 2016 · External reference
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: an in-depth review
10.3389/fnins.2022.970925 · 2022 · External reference
